1. Home /
  2. Pharmaceuticals

Pharmaceuticals

Novartis Secures Prostate Cancer Treatment With Endocyte Deal

Novartis Secures Prostate Cancer Treatment With Endocyte Deal

The Swiss drugmaker will pay $2.1 billion for Endocyte, justifying the Nasdaq-listed biotech's pivot to prostate treatment last year.

Jim Cramer on Slowing Job Growth in Once Robust Industries

Jim Cramer on Slowing Job Growth in Once Robust Industries

Jim Cramer breaks down the slowing job growth in once robust industries.

What Is Juul and Is It Bad for You?

What Is Juul and Is It Bad for You?

A "Juul" is an e-cigarette that looks like a USB flash drive and has become popular among younger, first-time smokers during the past several years. But, is it bad for you?

Pain Therapeutics Loses Half Its Value After Revealing Dispute With FDA

Pain Therapeutics Loses Half Its Value After Revealing Dispute With FDA

This small drug company loses half of its value. See why.

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

Eli Lilly's FDA-Approved Migraine Drug is Welcomed by the 38 Million Sufferers

With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.

CBD Doesn't Get You High, But Could Someday Eclipse the Entire Pot Industry

CBD Doesn't Get You High, But Could Someday Eclipse the Entire Pot Industry

Cannabidiol, or CBD, is a cannabis extract that's used to treat everything from pain to opiate addiction to PTSD. It doesn't get you high -- but advocates say that's the reason that CBD could soon eclipse the multibillion-dollar pot industry.

Newly Public Elanco Seeks to Innovate With Offering Proceeds

Newly Public Elanco Seeks to Innovate With Offering Proceeds

See what this little known veteran of a company has in store in the animal health industry.

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

What Does the Cannabis Industry Have in Common with the Dot-Com?

What Does the Cannabis Industry Have in Common with the Dot-Com?

Does the smoking cannabis industry share more than a few things in common with the Dot-com in the 1990s. Check out this podcast from the Real Money team.

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.